Not an official event of the ASCO Genitourinary Cancers Symposium. Not sponsored or endorsed by any of the co-sponsoring organizations of the ASCO Genitourinary Cancers Symposium.

Thursday, March 4, 2010
6:00-7:30 PM
Registration and Dinner Begin at 5:30 PM
The San Francisco Marriott
Club Room

The San Francisco Marriott
55 Fourth St.
San Francisco, CA
http://www.asco.org/ASCOv2/Meetings/Genitourinary+Cancers+Symposium

It is estimated that prostate cancer will account for more than 27,300 deaths in the United States during 2009, which makes this malignancy the second leading cause of cancer death among men. Most cases of prostate cancer are identified while the disease is still in the localized stage and is potentially curable with local radiotherapy or surgery; however, 5% of cases are identified at the advanced stage, which remains incurable despite recent advances in first- and second-line therapies. Patients with advanced disease are treated with surgery and/or hormonal therapy to deplete androgen levels in the body. While androgen deprivation can be very successful at slowing the progression of prostate cancer, eventually the cancer will become refractory to hormone therapy, necessitating the development of effective second-line treatments. Median survival in patients with castration-resistant prostate cancer (CRPC) can be extended to 18 months with first-line treatment using docetaxel-based chemotherapy. The recent development of new cancer vaccines, cell-based immunotherapies, monoclonal antibodies (MoAbs), and targeted agents for advanced prostate cancer could provide additional, more effective treatment options for this disease. This program will update healthcare professionals on the latest results from clinical trials that are investigating the safety and efficacy of these novel cancer immunotherapies and targeted drugs for the treatment of CRPC.

This activity is intended for medical oncologists, urologists, and other healthcare professionals who treat patients with prostate cancer.

Upon completion of this activity, participants will be able to

1. Evaluate recent data from clinical trials investigating the use of cancer vaccines and cell-based immunotherapies for the treatment of patients with CRPC.
2. Discuss the safety, efficacy, and mechanisms of action of MoAbs currently in development as immunotherapies for patients with CRPC.
3. Describe novel targeted agents currently undergoing late-phase clinical testing for advanced prostate cancer.

This symposium will use multiple methods of participation, including lectures, didactic presentations, and panel discussions to engage attendees and enhance the learning process.

Physicians: The CBCE™ (The Center for Biomedical Continuing Education) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The CBCE designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in this activity.

Physician Assistants: AAPA accepts certificates of participation for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.5 hours of Category 1 credit for completing this program.

The Evaluation and Request for Credit Form must be completed and returned to the CBCE following this activity to obtain credit. Participants will receive their certificate 4-6 weeks after the CBCE receives their form.

The CBCE gratefully acknowledges the educational grant provided by Dendreon Corporation. 

The CBCE fully complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of support services, please notify the CBCE staff at the symposium registration desk.

For further information, please contact the CBCE, 1707 Market Place Blvd., Suite 370, Irving, TX 75063; Phone: (214) 260-9024; Fax: (214) 260-0509; E-mail: info@thecbce.com.

The content and views presented in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of the CBCE or Dendreon Corporation. This material has been prepared based on a review of multiple sources of information but is not comprehensive. Participants are advised to critically appraise the information presented, and they are encouraged to consult the available literature on any product or device mentioned in this activity.